Orgenesis Stock Today
| ORGS Stock | USD 0.52 0.01 1.96% |
Performance10 of 100
| Odds Of DistressOver 69
|
Orgenesis is selling for under 0.52 as of the 24th of April 2024; that is 1.96 percent increase since the beginning of the trading day. The stock's lowest day price was 0.5. Orgenesis has more than 69 % chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. Equity ratings for Orgenesis are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of May 2022 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of March 2012 | Category Healthcare | Classification Health Care |
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 34.34 M outstanding shares of which 299.69 K shares are now shorted by private and institutional investors with about 3.78 trading days to cover. More on Orgenesis
Moving together with Orgenesis Stock
| 0.86 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
Moving against Orgenesis Stock
| 0.5 | EVO | Evotec SE ADR Earnings Call Today | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Orgenesis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Orgenesis' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Orgenesis or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO of Orgenesis Maryland Inc | Scott Carmer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Orgenesis report their recommendations after researching Orgenesis' financial statements, talking to executives and customers, or listening in on Orgenesis' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Orgenesis. The Orgenesis consensus assessment is calculated by taking the average forecast from all of the analysts covering Orgenesis. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Orgenesis' liquidity, profitability, solvency, and operating efficiency, Orgenesis is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Orgenesis is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Orgenesis' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Orgenesis' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Orgenesis' financial leverage. It provides some insight into what part of Orgenesis' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Orgenesis (ORGS) is traded on NASDAQ Exchange in USA. It is located in 20271 Goldenrod Lane, Germantown, MD, United States, 20876 and employs 146 people. Orgenesis is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.42 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Orgenesis's market, we take the total number of its shares issued and multiply it by Orgenesis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Orgenesis conducts business under Biotechnology sector and is part of Health Care industry. The entity has 34.34 M outstanding shares of which 299.69 K shares are now shorted by private and institutional investors with about 3.78 trading days to cover.
Orgenesis currently holds about 2.3 M in cash with (14.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Check Orgenesis Probability Of Bankruptcy
Ownership AllocationOrgenesis owns a total of 34.34 Million outstanding shares. Orgenesis has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Orgenesis Ownership Details
Orgenesis Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Orgenesis jumping above the current price in 90 days from now is about 55.42%. The Orgenesis probability density function shows the probability of Orgenesis stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 4.8629. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Orgenesis will likely underperform. Additionally, orgenesis has an alpha of 0.883, implying that it can generate a 0.88 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Orgenesis to move above the current price in 90 days from now is about 55.42 (This Orgenesis probability density function shows the probability of Orgenesis Stock to fall within a particular range of prices over 90 days) .
Orgenesis Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Orgenesis that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Orgenesis' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Orgenesis' value.| Instituion | Recorded On | Shares | |
| Prudential Financial Inc | 2023-12-31 | 11 K | |
| Ubs Group Ag | 2023-12-31 | 1.1 K | |
| Tsfg, Llc | 2023-12-31 | 1.1 K | |
| Bank Of America Corp | 2023-12-31 | 236 | |
| Wells Fargo & Co | 2023-12-31 | 216 | |
| Jpmorgan Chase & Co | 2023-12-31 | 141 | |
| Royal Bank Of Canada | 2023-09-30 | 117 | |
| Bnp Paribas Arbitrage, Sa | 2023-12-31 | 75.0 | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 38.0 | |
| Vanguard Group Inc | 2023-12-31 | 924.8 K | |
| Geode Capital Management, Llc | 2023-12-31 | 239.3 K |
Orgenesis Historical Income Statement
Orgenesis Income Statement is one of the three primary financial statements used for reporting Orgenesis's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Orgenesis revenue and expense. Orgenesis Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Orgenesis' Total Operating Expenses is comparatively stable compared to the past year. Minority Interest is likely to gain to about 26.1 M in 2024, whereas Gross Profit is likely to drop slightly above 599.5 K in 2024. View More FundamentalsOrgenesis Stock Against Markets
Picking the right benchmark for Orgenesis stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Orgenesis stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Orgenesis is critical whether you are bullish or bearish towards Orgenesis at a given time. Please also check how Orgenesis' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Orgenesis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
| All Next | Launch Module |
Orgenesis Corporate Directors
Orgenesis corporate directors refer to members of an Orgenesis board of directors. The board of directors generally takes responsibility for the Orgenesis' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Orgenesis' board members must vote for the resolution. The Orgenesis board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| David Sidransky | Director | Profile | |
| Yaron Adler | Director | Profile | |
| Etti Hanochi | Director | Profile | |
| Hugues Bultot | Director | Profile |
How to buy Orgenesis Stock?
Before investing in Orgenesis, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Orgenesis. To buy Orgenesis stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Orgenesis. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Orgenesis stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Orgenesis stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Orgenesis stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Orgenesis, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.
Already Invested in Orgenesis?
The danger of trading Orgenesis is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Orgenesis is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Orgenesis. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Orgenesis is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Orgenesis is a strong investment it is important to analyze Orgenesis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Orgenesis' future performance. For an informed investment choice regarding Orgenesis Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orgenesis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Orgenesis Stock analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Orgenesis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orgenesis. If investors know Orgenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orgenesis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.018 | Quarterly Revenue Growth (0.99) | Return On Assets (0.62) | Return On Equity (3.39) |
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Orgenesis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.